Mallinckrodt PLC (MNK) Given Average Recommendation of “Buy” by Brokerages
Mallinckrodt PLC (NYSE:MNK) has earned a consensus rating of “Buy” from the nineteen ratings firms that are covering the stock. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and fifteen have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $91.52.
Several analysts have recently weighed in on the company. Vetr downgraded Mallinckrodt PLC from a “buy” rating to a “hold” rating and set a $83.20 target price for the company. in a research report on Wednesday, August 17th. Mizuho lifted their target price on Mallinckrodt PLC from $83.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, August 3rd. JPMorgan Chase & Co. set a $85.00 target price on Mallinckrodt PLC and gave the stock a “hold” rating in a research report on Wednesday, August 3rd. Zacks Investment Research downgraded Mallinckrodt PLC from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Finally, Guggenheim reiterated a “buy” rating and set a $98.00 target price on shares of Mallinckrodt PLC in a research report on Wednesday, August 3rd.
Several large investors have recently added to or reduced their stakes in the company. Mizuho Asset Management Co. Ltd. increased its stake in Mallinckrodt PLC by 125.0% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 1,771 shares of the company’s stock worth $108,000 after buying an additional 984 shares during the period. Rational Advisors LLC purchased a new stake in Mallinckrodt PLC during the second quarter worth approximately $137,000. Advisor Group Inc. purchased a new stake in Mallinckrodt PLC during the second quarter worth approximately $196,000. Thrivent Financial for Lutherans purchased a new stake in Mallinckrodt PLC during the second quarter worth approximately $201,000. Finally, Laurel Wealth Advisors Inc. increased its stake in Mallinckrodt PLC by 0.5% in the second quarter. Laurel Wealth Advisors Inc. now owns 3,427 shares of the company’s stock worth $208,000 after buying an additional 16 shares during the period. 94.74% of the stock is owned by hedge funds and other institutional investors.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/mallinckrodt-plc-mnk-given-average-recommendation-of-buy-by-brokerages.html
Mallinckrodt PLC (NYSE:MNK) traded down 3.66% during trading on Tuesday, reaching $68.19. 715,710 shares of the company’s stock traded hands. Mallinckrodt PLC has a one year low of $50.90 and a one year high of $85.83. The firm has a market cap of $7.34 billion, a price-to-earnings ratio of 12.86 and a beta of 1.54. The company has a 50 day moving average of $74.03 and a 200 day moving average of $66.71.
Mallinckrodt PLC (NYSE:MNK) last released its earnings results on Tuesday, August 2nd. The company reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.00 by $0.20. Mallinckrodt PLC had a return on equity of 17.78% and a net margin of 16.39%. The business earned $970.60 million during the quarter, compared to the consensus estimate of $920.35 million. During the same period last year, the company earned $2.05 earnings per share. The business’s revenue for the quarter was up .6% compared to the same quarter last year. Equities research analysts predict that Mallinckrodt PLC will post $7.63 EPS for the current year.
Mallinckrodt PLC Company Profile
Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.